Enhancement of DNA cancer vaccine efficacy by combination with anti-angiogenesis in regression of established subcutaneous B16 melanoma

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1197-1203

  Chan, Ray Chun Fai ^a   Gutierrez, Benjamin ^a   Ichim, Thomas E ^b   Lin, Feng ^a  

^a Inovio Biomedical Corporation   (United States)

^b Medistem Inc   (United States)

Author keywords

Antiangiogenesis; DNA vaccine; Electroporation; Melanoma

Indexed keywords

ANGIOSTATIN; CANCER VACCINE; DNA VACCINE; ENDOSTATIN; EPHRIN RECEPTOR B2; GLYCOPROTEIN GP 100; INVARIANT CHAIN WITH CLIP REPLACED BY PAN DR EPITOPE; MELANOMA VACCINE; PLASMID DNA; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; MELANOMA B16; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNITY; VACCINATION;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; CANCER VACCINES; COMBINED MODALITY THERAPY; ELECTROPORATION; ENDOSTATINS; FEMALE; GP100 MELANOMA ANTIGEN; HUMANS; IMMUNOTHERAPY; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; RECEPTOR, EPHB4; TUMOR CELLS, CULTURED; VACCINATION; VACCINES, DNA;

EID: 70449436131     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000555     Document Type: Article

References (27)

1. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
2. Griffioen AW: Anti-angiogenesis: making the tumor vulnerable to the immune system. Cancer Immunol Immunother 57: 1553-1558, 2008.
3. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW and Folkman J: Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101: 1055-1063, 1998.
4. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, Eliceiri BP and Reisfeld RA: A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 8: 1369-1375, 2002.
5. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
6. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328, 1994.
7. Mullen JT, Donahue JM, Chandrasekhar S, Yoon SS, Liu W, Ellis LM, Nakamura H, Kasuya H, Pawlik TM and Tanabe KK: Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse Endostatin. Cancer 101: 869-877, 2004.
8. Scehnet JS, Ley EJ, Krasnoperov V, Liu R, Manchanda PK, Sjoberg E, Kostecke AP, Gupta S, Kumar SR and Gill PS: The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113: 254-263, 2009.
9. Xu YF, Zhu LP, Hu B, Rong ZG, Zhu HW, Xu JM, Wu ZW, Wang JJ and Xu GX: A quantitative method for measuring the anti-tumor potency of recombinant human Endostatin in vivo. Eur J Pharmacol 564: 1-6, 2007.
10. Rosenberg SA: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 88: 1635-1644, 1996.
11. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL and Heller R: Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 26: 5896-5903, 2008.
12. Heller R, Schultz J, Lucas ML, Jaroszeski MJ, Heller LC, Gilbert RA, Moelling K and Nicolau C: Intradermal delivery of interleukin-12 plasmid DNA by in vivo electroporation. DNA Cell Biol 20: 21-26, 2001.
13. Isaka Y and Imai E: Electroporation-mediated gene therapy. Expert Opin Drug Deliv 4: 561-571, 2007.
14. Lucas ML, Heller L, Coppola D and Heller R: IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16.F10 melanoma. Mol Ther 5: 668-675, 2002.
15. Luxembourg A, Evans CF and Hannaman D: Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol Ther 7: 1647-1664, 2007.
16. + T cells. J Immunol 179: 4741-4753, 2007.
17. Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG, Harper LB, Beare CM, Bagdon WJ and Nichols WW: Plasmid DNA vaccines: investigation of integration into host cellular DNA following intramuscular injection in mice. Intervirology 43: 258-272, 2000.
18. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC and Griffioen AW: Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 20: 621-630, 2006.
19. Dirkx AE, Oude Egbrink MG, Wagstaff J and Griffioen AW: Monocyte/ macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 80: 1183-1196, 2006.
20. + T-cell immune responses and enhances vaccine potency. Mol Ther 15: 1211-1219, 2007.
21. Liu W, Ahmad SA, Jung YD, Reinmuth N, Fan F, Bucana CD and Ellis LM: Coexpression of ephrin-Bs and their receptors in colon carcinoma. Cancer 94: 934-939, 2002.
22. Nakamoto M and Bergemann AD: Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59: 58-67, 2002.
23. Frumento G, Piazza T, Di Carlo E and Ferrini S: Targeting tumor-related immunosuppression for cancer immunotherapy. Endocr Metab Immune Disord Drug Targets 6: 233-237, 2006.
24. Kim R, Emi M and Tanabe K: Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 146: 189-196, 2006.
25. Cichon T, Jamrozy L, Glogowska J, Missol-Kolka E and Szala S: Electrotransfer of gene encoding Endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther 9: 771-777, 2002.
26. Moser TL, Stack MS, Asplin I, Enghild JJ, Hojrup P, Everitt L, Hubchak S, Schnaper HW and Pizzo SV: Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA 96: 2811-2816, 1999.
27. Persano L, Crescenzi M and Indraccolo S: Anti-angiogenic gene therapy of cancer: current status and future prospects. Mol Aspects Med 28: 87-114, 2007.